Gastrointestinal cancers, including gastric cancer and colorectal cancer, remain a major global health challenge. With high incidence rates and poor outcomes—especially in advanced-stage disease—patients urgently need more effective and better-tolerated treatment options. Traditional chemotherapy, while widely used, often delivers limited benefits at the cost of significant toxicity.

Today, innovation is changing this landscape.

Fruquintinib, a targeted anticancer therapy independently developed in China, is emerging as a powerful new option for patients with gastrointestinal malignancies—bringing precision, efficacy, and renewed hope to those facing limited therapeutic choices.

Precision Targeting That Makes a Difference

Fruquintinib is a highly selective, oral small-molecule tyrosine kinase inhibitor designed to precisely target VEGFR-1, VEGFR-2, and VEGFR-3—key drivers of tumor angiogenesis.

By effectively blocking the formation of tumor blood vessels, fruquintinib starves tumors of the nutrients they need to grow and spread. This precise mechanism allows fruquintinib to deliver strong antitumor activity while minimizing damage to normal tissues, offering patients a treatment that is both effective and manageable.

Proven Efficacy, Validated Globally

The clinical value of fruquintinib is supported by robust, high-quality Phase III clinical evidence.

• FRESCO, a landmark multicenter Phase III trial in China, established fruquintinib as an effective third-line therapy for advanced colorectal cancer, significantly improving both progression-free survival (PFS) and overall survival (OS).

• FRESCO-2, a global Phase III study, further confirmed these benefits across diverse regions and populations, demonstrating fruquintinib’s broad applicability on the international stage.

In heavily pretreated advanced colorectal cancer patients, fruquintinib:

• Significantly prolonged median PFS (up to 3.7 months)

• Reduced the risk of disease progression by 68%–74%

• Extended median OS to 7.4–9.3 months, with a 34%–35% reduction in mortality risk

These results firmly position fruquintinib as a globally competitive targeted therapy backed by strong evidence.

Expanding Horizons: From Colorectal Cancer to Gastric Cancer

Originally approved in China as a standard third-line treatment for advanced colorectal cancer, fruquintinib continues to expand its clinical footprint.

The FRUTIGA study demonstrated that fruquintinib combined with paclitaxel delivers meaningful clinical benefit as second-line therapy for advanced gastric cancer. This breakthrough offers physicians a new, effective treatment strategy and provides gastric cancer patients with renewed hope beyond conventional options.

This expansion reflects not only the versatility of fruquintinib, but also the growing strength of China-led innovation in oncology.

Real-World Success Stories That Inspire Confidence

Beyond clinical trials, fruquintinib has demonstrated compelling value in real-world practice.

• Advanced colorectal cancer patients who had exhausted standard treatments achieved durable tumor control when fruquintinib was combined with immunotherapy, with some experiencing long-term partial responses.

• Advanced gastric cancer patients showed rapid tumor shrinkage and sustained disease stabilization when treated with fruquintinib-based combination regimens.

These real-world outcomes highlight fruquintinib’s flexibility, reliability, and potential in personalized treatment strategies.

Designed for Long-Term Treatment: Manageable Safety Profile

Fruquintinib is associated with predictable and manageable adverse events, including hypertension, proteinuria, and hand–foot syndrome. With proactive monitoring and appropriate dose management, most patients are able to remain on treatment and continue to benefit from therapy.

This balance of strong efficacy and controllable safety makes fruquintinib well suited for long-term disease management in advanced cancer settings.

From China to the World: Innovation with Global Impact

Fruquintinib represents a milestone in China’s biopharmaceutical journey—from learning and following to innovating and leading. As one of the first China-developed targeted anticancer therapies to gain both domestic and international recognition, fruquintinib is helping reshape global perceptions of Chinese innovation.

By delivering high-quality, evidence-based cancer treatment options, fruquintinib is making a meaningful contribution to global oncology care.

Looking Ahead: Combination Strategies and Personalized Care

Ongoing research continues to unlock new possibilities for fruquintinib. Combination strategies with immunotherapy or chemotherapy are showing promising results, particularly for patients with limited options such as MSS/pMMR colorectal cancer.

As precision medicine advances, fruquintinib is poised to play an increasingly important role across multiple tumor types—helping patients live longer and better lives.

Fruquintinib: Innovation That Brings Hope

More than a medicine, fruquintinib is a symbol of innovation, precision, and progress. With its strong scientific foundation, proven clinical benefits, and expanding global presence, fruquintinib is redefining what targeted therapy can achieve for gastrointestinal cancer patients.

HKDengyueMed, a Chinese pharmaceutical import and export wholesaler, is committed to advancing global health by promoting the international circulation of innovative anticancer drugs, providing valuable treatment options for patients worldwide.

From China to the world, fruquintinib is lighting the way forward in cancer treatment.